.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Julphar
Boehringer Ingelheim
Covington
Novartis
Accenture
QuintilesIMS
US Department of Justice
AstraZeneca
Dow

Generated: June 27, 2017

DrugPatentWatch Database Preview

Indium in-111 pentetreotide kit - Generic Drug Details

« Back to Dashboard

What are the generic sources for indium in-111 pentetreotide kit and what is the scope of indium in-111 pentetreotide kit patent protection?

Indium in-111 pentetreotide kit
is the generic ingredient in one branded drug marketed by Mallinkrodt Nuclear and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Indium in-111 pentetreotide kit has twelve patent family members in eight countries.

There are twenty-three drug master file entries for indium in-111 pentetreotide kit. Two suppliers are listed for this compound.

Summary for Generic Name: indium in-111 pentetreotide kit

Tradenames:1
Patents:1
Applicants:1
NDAs:1
Drug Master File Entries: see list23
Suppliers / Packagers: see list2
Clinical Trials: see list586
Drug Prices:see low prices
DailyMed Link:indium in-111 pentetreotide kit at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mallinkrodt Nuclear
OCTREOSCAN
indium in-111 pentetreotide kit
INJECTABLE;INJECTION020314-001Jun 2, 1994RXYesYes6,123,916► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: indium in-111 pentetreotide kit

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mallinkrodt Nuclear
OCTREOSCAN
indium in-111 pentetreotide kit
INJECTABLE;INJECTION020314-001Jun 2, 19945,384,113► Subscribe
Mallinkrodt Nuclear
OCTREOSCAN
indium in-111 pentetreotide kit
INJECTABLE;INJECTION020314-001Jun 2, 19945,776,894► Subscribe
Mallinkrodt Nuclear
OCTREOSCAN
indium in-111 pentetreotide kit
INJECTABLE;INJECTION020314-001Jun 2, 19945,753,627► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: indium in-111 pentetreotide kit

Country Document Number Estimated Expiration
Belgium1004645► Subscribe
ItalyRM910115► Subscribe
United Kingdom2241167► Subscribe
France2658421► Subscribe
Switzerland683318► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Colorcon
Moodys
Teva
Daiichi Sankyo
Mallinckrodt
Harvard Business School
Medtronic
Fish and Richardson
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot